(Reuters) - In a separate release, the New York-based drugmaker said it earned $690 million, or 35 cents per share, compared with $714 million, or 36 cents per share, in the year-ago period.
Excluding special items, the company earned 38 cents per share. Analysts on average expected 23 cents per share, according to Reuters Estimates. The company said its better-than-expected results were attributable largely to lower operating expenses and a favorable tax rate.
Read more at Reuters.com Business News
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment